Thus, preclinical studies with ALS models are needed to test pharmacological inhibitors of the neuronal NF-κB signaling pathway for their potency to confer neuroprotection and, especially, to mitigate TDP-43 pathology. The gene discussed is NFKB1; the disease is amyotrophic lateral sclerosis.